|[February 19, 2013]
Research and Markets: Regenerative medicine and Stem cells Partnering Terms and Agreements
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/tb9cmt/regenerative)
has announced the addition of the "Regenerative
medicine and Stem cells Partnering Terms and Agreements" report
to their offering.
The Regenerative Medicine and Stem Cells Partnering Terms and Agreements
report provides comprehensive understanding and unprecedented access to
the Regenerative medicine and Stem cells partnering deals and agreements
entered into by the worlds leading healthcare companies.
- Trends in regenerative medicine and stem cells deals
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why
companies enter regenerative medicine and stem cells partnering deals.
The majority of deals are development stage whereby the licensee obtains
a right or an option right to license the licensors regenerative
medicine and stem cells technology. These dealstend to be
multicomponent, starting with collaborative R&D, and commercialization
This report provides details of the latest regenerative medicine and
stem cells agreements including cell therapy agreements announced in the
Understanding the flexibility of a prospective partner's negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered - contract documents provide this insight where press releases
and databases do not.
This report contains a comprehensive listing of all regenerative
medicine and stem cells partnering deals announced since 2008 including
financial terms where available including over 550 links to online deal
records as disclosed by the deal parties. In addition, where available,
records include contract documents as submitted to the Securities
Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner's flexibility on a wide range of important issues,
many of which will have a significant impact on each party's ability to
derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in regenerative medicine and stem cells dealmaking
Chapter 3 - Leading regenerative medicine and stem cells deals
Chapter 4 - Bigpharma regenerative medicine and stem cells deals
Chapter 5 - Regenerative medicine and stem cells partnering contracts
Chapter 6 - Regenerative medicine and stem cells dealmaking by
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
- Kyowa Hakko Kirin
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/tb9cmt/regenerative
[ Back To Technology News's Homepage ]